0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editorial |

New Lessons From the Alzheimer's Disease Neuroimaging Initiative

Stephen Salloway, MD, MS
Arch Neurol. 2011;68(1):19-21. doi:10.1001/archneurol.2010.344.
Text Size: A A A
Published online

Extract

The Alzheimer's Disease Neuroimaging Initiative (ADNI) is a public sector–industry partnership founded in 2004 to develop biomarkers to predict the progression from normal aging or mild cognitive impairment (MCI) to the dementia phase of Alzheimer disease (AD).1 The ADNI has created the infrastructure to conduct a longitudinal observational trial, standardized methods for multicenter biomarker analysis, and established a widely available data repository. The study consists of 3 groups of individuals aged 55 to 90 years. Individuals with normal cognition, amnestic MCI, and mild AD are followed up annually with volumetric magnetic resonance imaging and positron emission tomography with fluorine-18–labeled deoxyglucose scans,cognitive and neurological evaluations, and analysis of cerebrospinal fluid (CSF) markers in individuals consenting to examination. In its short lifespan, this valuable data set has produced important advances in biochemical and imaging biomarkers of cognitive decline. Shaw and colleagues2 recently reported further evidence that lowering of CSF Aβ42 and increases in total tau are early changes predicting progression from amnestic MCI to AD. The ADNI is also designed to measure clinical factors affecting cognitive decline. In this issue of the Archives, Schneider and colleagues3 add to the ADNI literature by reporting the differences in the 2-year cognitive and functional performance ratings of 402 MCI patients and 188 patients with mild AD in the ADNI cohort who were taking and not taking antidementia medications. The ratings included the AD Assessment Scale–cognitive subscale (ADAS-cog), Mini-Mental State Examination (MMSE), Clinical Dementia Rating (CDR) scale, and Functional Activities Questionnaire. Baseline and 2-year outcomes for MCI patients were compared for 3 groups: patients receiving no treatment, those receiving a cholinesterase inhibitor (ChEI) only, and those receiving combination treatment. The AD patients receiving ChEIs were compared with those receiving combined treatment.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

81 Views
1 Citations
×

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles
Jobs
JAMAevidence.com

The Rational Clinical Examination: Evidence-Based Clinical Diagnosis
Make the Diagnosis: Does This Patient With Headaches Have a Migraine or Need Neuroimaging?

The Rational Clinical Examination: Evidence-Based Clinical Diagnosis
Original Article: Does This Patient With Headache Have a Migraine or Need Neuroimaging?

brightcove.createExperiences();